Evidence‐practice gaps in <scp>P2Y₁₂</scp> inhibitor use after hospitalisation for acute myocardial infarction: findings from a new population‐level data linkage in Australia

Post-hospitalisation use of P2Y₁₂ inhibitor therapy in AMI patients is low and varies substantially by hospital of discharge. Our findings suggest strategies addressing both health system (hospital and physician) and patient factors are needed to close this evidence-practice gap.